Neurimmune Holding ^Investor

Neurimmune Holding is a biopharmaceutical company that focuses on developing immunotherapeutics to treat and prevent human disorders with high unmet medical needs. They use a unique platform called Reverse Translational Medicine\u2122 to create monoclonal antibodies that closely resemble those found in healthy elderly individuals. These antibodies have unique properties that make them effective and safe for use in treating various diseases. Neurimmune's pipeline includes programs for a range of disease-related targets and specific target conformations, including disease-associated proteins and physiological conformations involved in major disease pathways.